# Personalizing the Pressure Reactivity Index for Neurocritical Care Decision Support

Jennifer K. Briggs, J.N. Stroh, Brandon Foreman, Soojin Park, the TRACK-TBI Study Investigators, Tellen D. Bennett[†], David J. Albers[†]

*Abstract*— **Neurocritical care patients may benefit from personalized treatment based on their cerebral autoregulatory function. The pressure reactivity index is an important, prevalent metric used to estimate the state of a patient's cerebral autoregulation and guide clinical decision-making. However, the pressure reactivity index is a noisy metric, highly sensitive to hyperparameter choices, and is associated with uncertainty that may be influenced by patient demographic. In this manuscript, we develop a methodology that increases robustness and reduces the uncertainty of the pressure reactivity index. Using data from traumatic brain injury patients and novel simulated data, we first show that error in the pressure reactivity index is sensitive to the averaging and correlation window sizes used in its calculation. We then show that this error is patient and heartrate specific. The heartrate-sensitive error has vital implications for extending the use of the pressure reactivity index to patients with different regular heart rates, such as pediatric populations. To address this sensitivity, we develop a new algorithm that personalizes the pressure reactivity index calculation by adjusting for patient heart rate at resolutions of single heartbeats. Implementing our heartbeat-based pressure reactivity index methodology decreases error, uncertainty, and sensitivity, allowing the pressure reactivity index to be more clinically useful and robust to variability across patient populations. We also leverage our data and analysis to identify optimal averaging windows of 9-10 seconds and correlation windows from 40-55 samples in the standard method.**

[†] indicates co-senior author

J.K.B and D.J.A are with Department of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora CO (email: Jennifer.Briggs@cuanschutz.edu)

J.N.S, T.D.B, and D.J.A are with Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora CO

T.D.B is with Department of Pediatrics (Critical Care Medicine), University of Colorado Anschutz Medical Campus, Aurora CO

S.P is with Department of Neurology, Columbia University Irving Medical Center, New York-Presbyterian Hostpital, New York, NY

S.P. and D.J.A are with Department of Biomedical Informatics, Columbia University Irving Medical Center, New York-Presbyterian Hostpital, New York, NY

B.F is with Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH

We acknowledge National Institutes of Health R01s LM006910 "Discovering and applying knowledge in clinical databases," and "Mechanistic machine learning," LM012734 to DJA, National Science Foundation (NSF) Graduate Research Fellowship DGE-1938058 Briggs to JKB

We thank the following TRACK-TBI Investigators: Neeraj Badjatia, MD, University of Maryland; Ramesh Grandhi, MD MS, University of Utah; Michael McCrea, PhD, Medical College of Wisconsin; Randall Merchant, PhD, Virginia Commonwealth University; Laura B. Ngwenya, MD, PhD, University of Cincinnati; Claudia Robertson, MD, Baylor College of Medicine; David Schnyer, PhD, UT Austin; John K. Yue, MD, University of California, San Francisco

## I. INTRODUCTION

Neurological injuries are a prevalent cause of long-term disability and death. In the United States, there are approximately 64,000 traumatic brain injury (TBI)-related deaths[1] and 160,264 stroke-related deaths[2] annually. Poor patient outcomes often result from secondary insults such as ischemic events or acute underperfusion of the brain following initial neurological injury. Therefore, optimizing perfusion to reduce secondary injury is a key goal in clinical decision support.

Cerebral perfusion, typically represented as cerebral blood flow (CBF), depends on cerebral vascular resistance (CVR) and cerebral perfusion pressure (CPP). CPP is the pressure gradient between mean intracranial pressure (mICP) and mean arterial blood pressure (mABP) (eq. 1). Current clinical guidelines recommend targeting mICP below 20-25 mmHg to mitigate the risk of secondary injuries[3]. However, a precision medicine approach that considers the state of the patient's vasculature may improve patient outcomes.

$$CBF = \frac{CPP}{CVR} = \frac{mABP - mICP}{CVR} \qquad (1)$$

Cerebral autoregulation (CA) is an intrinsic mechanism of the cerebral vasculature that maintains adequate cerebral blood flow over large pressure gradients by altering cerebral vascular resistance[4], [5]. CA can be impaired in patients with neurological injuries. Retrospective studies have shown that patients have better functional outcomes when their CPP is close to a value that optimizes CA, known as CPPopt[6], [7]. Therefore, in contrast to current population wide ICP-guided therapy, patients may benefit from patient-specific therapy where a patients CPP is targetted to their CPPopt[8], [9]. Recent clinical trials are advancing the use of CPPopt-guided treatment toward becoming a new standard of care[11], [12]. Proper evaluation of CA function is crucial for accurately estimating CPPopt.

CA function can be estimated using various metrics, including transfer function analysis and the pressure reactivity index (PRx)[5], [6], [10]. PRx is the metric used in CPPopt-guided therapy. PRx is calculated by first taking a non-overlapping moving average of ICP and ABP time series over a specific window size and then calculating the Pearson correlation coefficient between a given number of averaged mean ABP and mean ICP samples[13]. A graphical depiction of the PRx calculation is shown in **Figure 1**. Averaging is done to remove frequencies that occur faster than CA operates[14]–[16]. Correlation is calculated with the assumption that intact CA

should be able to buffer changes in ABP before they are transmitted into ICP. Thus, a higher correlation indicates more impaired CA. The values of the averaging and correlation window are hyperparameters in the PRx calculation because they are chosen *a priori*[17], [18]. Variable values for these hyperparameters are present in the literature (see **Table I**) and the impact of their choice is not well understood.

| Averaging Window (seconds) | Number of Samples for Correlation |
|---|---|
| 10 | 40[19] |
| *10* | *30* (most common[20])[21]–[28] |
| 5 | 40[10], [13], [29]–[31] |
| 15 | 30[32]* |
| 6 | 40[6], [33], [34] |

TABLE I

COMMON HYPERPARAMETERS USED TO CALCULATE PRx

As PRx popularity is gaining popularity for use in guiding clinical decisions, it is important to identify the correct hyperparameters and the algorithm itself. We hypothesize that the optimal hyperparameters may be patient-specific, necessitating a personalized PRx algorithm or hyperparameter set to ensure accurate PRx estimation across all patient demographics.

The purpose of this manuscript is threefold. *First*, we investigate the robustness and uncertainty of the PRx calculation across hyperparameters and patients to emphasize the need for a personalized PRx algorithm. *Second*, we test the hypothesis that a personalized parameterization of the PRx algorithm will provide a more robust and stable estimation of CA. *Third*, we investigate optimal hyperparameters for improving the robustness of PRx in the standard method.

## II. METHODS

### Data

**Patient Data** Patient data was taken from patients enrolled in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study[35], a prospective, multicenter study of patients with traumatic brain injury. Written informed consent was obtained and the study was approved by the institutional review boards of enrolling sites. For this investigation, we included patients undergoing multimodality monitoring from a single center within the TRACK-TBI study to ensure standardized physiological measurements and clinical practice. However, the entire TRACK-TBI cohort was used for rescaling simulated data. Patient demographics are given in **Table II**.

Data from 11 patients were extracted and segmented into four-hour windows, which is the time recommended to calculate a target cerebral perfusion pressure (CPPopt)[30], resulting in 21 patient datasets. These windows were analyzed beacause missing or erroneous data made up less than $10\%$ of the four-hour time period. Erroneous data was defined as ABP $> 400$ mmHg or $< 0$ mmHg and ICP $> 100$ mmHg or $< 0$ mmHg. All erroneous data were set to null. Segments of

*Howells recommends using 15-50 second averages but does not use any correlation window. For consistency, we chose correlations that would result in the same amount of data captured in [24], [25](5 minutes)

| Variable† | TRACK-TBI Physiology Cohort (UCMC), n=11 |
|---|---|
| *Demographics* | |
| Age, years | 41.8±16.5 |
| Sex, male | 9 (82) |
| *Injury Characteristics* | |
| - Motor Vehicle Traffic Accident | 6 (55) |
| - Fall | 4 (36) |
| - Other | 1 (1) |
| Time from Injury to Admission, hours | 1 [0.7-1.5] |
| Admission GCS | 3 [3-5] |
| Admission GCS Motor Subscore | 1 [1-3] |
| Admission pupils, one or neither reacting | 7 (64) |
| Injury Severity Score | 25.5± 9.1 |
| Patients Requiring Decompressive Hemicraniectomy | 6 (55) |
| *Monitoring Data* | |
| Time from Injury to Moberg CNS Data, hours | 7.3 [6.0-16.5] |
| Duration of Available Moberg CNS Data, hours | 39.5 [32.2-100.7] |
| ICP Monitoring | 11 (100) |
| Time from Injury to ICP Monitoring, hours | 6.5 [5.7-11.6] |
| *ICP Monitor Type* | |
| - Parenchymal Monitor | 9 (82) |
| - External Ventricular Drainage Catheter | 2 (18) |
| - Both | |
| *Outcome* | |
| Hospital Length of Stay, days | 15.1 [14.2-22.3] |
| In-Hospital Mortality | 6 (55) |
| 6-Month Mortality | 8 (73) |
| 6-Month Glasgow Outcome Scale-Extended | 1 [1-2] |

TABLE II

PATIENT CHARACTERISTICS AND MONITORING DATA. INJURY WAS CLOSED FOR ALL PATIENTS. ALL PATIENTS HAD MULTIMODAL MONITORING, INCLUDING ICP WAVEFORMS, EEG, AND PBTO2.

erroneous data less than one second were filled through linear interpolation. The averaging scheme for gaps larger than one second was left as null and not included in the correlation.

**Simulated Data** Continuous evaluation of global cerebral autoregulation in humans is not currently possible. Therefore, validating which hyperparameter would give the true PRx estimation and calculating the error is infeasible for patient data. To quantify the error, we created simulated data based on physiologically relevant signals. **Figure 2** shows a graphical description of simulated data creation. We created 200 simulated datasets, each containing ABP and ICP for the three CA phenotypes: "Functional CA," "Impaired CA," and "Absent CA," resulting in 600 example time series. This was based on studies showing that as CA becomes impaired, slower frequencies are translated from ABP to ICP[24], [36], [37].

First, five different waveforms were created over four hours of $125Hz$ resolution data (**Fig. 2.1**). These waveforms were based on frequencies present in documented patient waveforms, including heart rate and respiration, which are present in both ABP and ICP; B-waves, which are present only in ICP and represent processes in ICP independent of ABP[39];

†All data reported as mean+/-standard deviation, median [interquartile range], or proportion (%) as appropriate

Fig. 1. Algorithm for calculating PRx. a: ABP (blue) and ICP (red) are averaged over a non-overlapping averaging window. b: $n$ number of these averaged samples are collected, and the Pearson correlation coefficient is calculated (c) on a 4/5 overlap sliding window.

Fig. 2. Graphical depiction of the creation of simulated data set. Step 1 shows the power spectrum of the six base frequencies (Table III) used to create ICP and ABP. Blue indicates a representative ABP waveform. In each ABP waveform, the heartrate frequency was randomly selected between 40-140 bpm and was scaled to match the amplitude of a randomly selected patient from the TRACK-TBI dataset. Red indicates three ICP waveforms created from combinations of the base frequencies. Three CA phenotypes were created: Functional CA, Impaired Ca, and Absent CA. The frequencies used to create each ICP waveform are given above the red arrows

| Signal Name | Physiologic Interpretation | Rate or Period | |
|---|---|---|---|
| $F1$ | Heart Rate | 40-140 beats per minute | Scaled in frequency and amplitude to match randomly selected patient from UC Cincinnati dataset |
| $F2$ | Respiration | 10 breaths per minute | |
| $F3$ | Random | 30 second period | Meant to emulate random external changes to the patient, slow enough for CA to buffer[37], [38] |
| $F4$ | Waves only present in ICP | 90 second period | Found only in ICP[39] |
| $F5$ | Random | 16-minute period | Meant to emulate slow random external changes to the patient |

TABLE III
PHYSIOLOGICALLY RELEVANT FREQUENCIES USED IN SIMULATED DATA

and two random waves, which are meant to emulate random external changes in ABP or ICP (**Table III**). Heart rate was randomly chosen to lie between 40-140 beats per minute to emulate all possible average heart rates in patients. Care was taken such that these frequencies were not harmonics with each other. From these base frequencies, we created three ICP waveforms (**Fig. 2.2a**). In functional CA, ICP should reflect heart rate, respiration, and B-waves[10], [24], [36], [40]. Therefore, ICP for simulated patients with functional CA was defined as: $ICP = F1 + F2 + F4$. In impaired CA passes, fast frequencies and decreasing portions of the slower waves to pass into ICP from ABP[24], [36], [37]. Therefore, ICP for simulated patients with impaired CA was defined as $ICP = F1 + F2 + F3/1000 + F4 + F5/1000$. Frequency $F1$ and $F2$ represent heartbeats and respiration which represents the fast frequencies fully passed into ICP. Frequencies $F3$ and $F5$ represent slower frequencies that impaired CA should dampen. $F3$ and $F5$ were were divided by 1000 to represent dampening of ICP. In absent CA, PRx assumes that most or all of the frequencies present in ABP will be reflected in ICP. Therefore, ICP for simulated patients with absent CA was defined as $ICP = F1 + F2 + F3 + F4 + F5$. ABP was created by summing all frequencies except for B-Waves (F4).

ICP waveforms are caused by traveling ABP waves, which causes ICP to be lagged behind ABP by approximately 6.8 seconds[41]. Therefore, ICP waveforms were shifted by 6.8 seconds. ICP and ABP were then rescaled according to physiological values for each dataset. To obtain physiological rescaling values, we extracted full timecourses of ABP and ICP from all patients within the TrackTBI dataset. We fit a gamma distribution to each patient's ICP and ABP data using Matlab's *fitdist* function. For each dataset, we randomly selected a representative patient and rescaled ICP and ABP according to that patient's distribution. As CA is one of many factors contributing to ICP value, we rescaled all three ICP waveforms to the same amplitude.

PRx is meant to capture the correlation between ABP and ICP after removing effects of heart rate and respiration, 'True' PRx was defined as the correlation coefficient over the whole

waveform between $F3$ and $F5$ in ABP and all frequencies slower than $F2$ in ICP.

### Analysis

To assess PRx over a wide range of hyperparameters, we first calculated PRx for every hyperparameter in each dataset, then calculated the error and sensitivity.

**Calculating PRx:** To test the sensitivity of PRx estimation to hyperparameters, we calculated PRx for every combination of averaging windows between 1 and 30 seconds and every correlation window between 2 and 65 averaged samples. We chose this broad range to capture every methodology presented in the literature. According to standard methods, averaging windows did not overlap [24] and correlation windows are calculated so that the number of samples overlaps by 4/5. All calculations were done in Matlab and are publically available at: https://github.com/jenniferkbriggs/PRx. Unless otherwise noted, the reported PRx value is the median PRx across the four-hour dataset. Since the PRx calculation has high variance (noisy), we chose to use the median as it is more robust to noise than the mean.

**Empirical Error:** To assess the accuracy of PRx estimation in the patient data set, we define error as statistical estimator bias, which is the difference between the estimated PRx value and the true PRx value (or average for patient data) as the number of data points increases. To calculate empirical error from patient data, we first extracted the PRx estimation for each patient using the five common PRx hyperparameters outlined in **Table I**. Because each method is based on different time windows, the time over which each PRx value is computed was slightly different. Therefore, the output of each PRx method was interpolated to compare values directly. The empirical error and standard deviation in error for each patient was calculated according to equations 2 and 3. At each time point, $PRx_{t_n,j}$ is averaged over PRx estimation from the range of common hyperparameters (averaging windows between 5-20 seconds and correlation windows between 20-50 seconds) to define $\overline{PRx}$, which is used as a center point for error calculations.

$$\text{Empirical Error}_j = \frac{1}{T_N} \sum_{n=1}^{T_N} (\widehat{PRx}_{t_n,j} - \overline{PRx_{t_n}}) \quad (2)$$

$$\overline{PRx(t_n)} = \frac{1}{J} \sum_{j=1}^{J} PRx(t_n)_j \quad (3)$$

Where $t_n$ is the time point, $T_N$ is the total time, $j$ is the hyperparameter pair, $J$ is the total number of hyperparameters analyzed, and $\widehat{PRx}$ is the estimated PRx for hyperparameter $j$ and time $t_n$.

In simulated data where there is a ground truth PRx value, error is given by equation 2 but $\overline{PRx_{t_n}}$ is replaced with the predefined 'true' PRx value.

**Calculating Sensitivity:** To assess the sensitivity of PRx estimation to hyperparameters, we iterated through every hyperparameter pair and calculated the percent difference between the PRx value estimated using the hyperparameter pair and the PRx value estimated a small change in hyperparameter pairs

(e.g., averaging with $\pm 1$ second or correlating $\pm 1$) (equation 4). Sensitivity is interpreted as the average percent change in PRx value given a small change in hyperparameter choice.

$$\text{Sensitivity} = \frac{1}{4N} \sum_{i=1}^{N} \frac{PRx(n+1) - PRx(n)}{PRx(n)}$$
$$+ \frac{PRx(n-1) - PRx(n)}{PRx(n)} + \frac{PRx(n+Av) - PRx(n)}{PRx(n)} \quad (4)$$
$$+ \frac{PRx(n-Av) - PRx(n)}{PRx(n)}$$

$N$ is the number of unique hyperparameter pairs and $PRx(n)$ is the PRx for a given hyperparameter, and $Av$ is the number of averaging windows, allowing us to index into a 2D matrix using one number.

The range of PRx values was calculated as the difference between the PRx estimation from the hyperparameter with the largest median PRx value and the PRx estimation from the hyperparameter with the smallest median PRx value.

### Developing Personalized Algorithm for PRx Estimation

To investigate our hypothesis that personalizing the PRx algorithm by averaging over patient heartbeat would provide a more robust and stable estimation of CA, we first identified all heartbeats in patient signals. Heartbeats in patients and simulated data were found using a sliding peak identification method on ABP. Data were segmented into one-minute and one-second windows with one-second overlap. A heartbeat is defined from the beginning of systole to the end of diastole. In each window, the beginning of each systolic phase was identified using Matlab's *findpeaks* function of the inverted ABP segment. To ensure the dicrotic notch was not mistaken as a peak, the minimum peak prominence was set to be half of the range of max ABP to min ABP during the minute window (see **Fig. 4a.** for example heartbeat identification). For sections of missing data, heartbeats were imputed as the average heart rate of the previous minute-long section. PRx was calculated as previously, but averaging windows were calculated using a given number of heartbeats rather than seconds.

### Identifying Optimal Hyperparameters

Optimal hyperparameters were identified using both patient and simulated data. For patient data, the standard deviation (SD) of error in PRx estimation was the standard deviation of the estimator error across the 21 datasets. We defined optimal thresholds for each of the four metrics as the thresholds which minimized error or SD of error and that yielded hyperparameters consistent with the other metrics. SD of error in PRx for patient data had a threshold of 0.022, and 0.22 for simulated. For average error of PRx we used a threshold $|0.01|$ for patient data, and $|0.22|$ for simulated data.

The standard deviation of estimator error over time, given by equation 5 was calculated by first interpolating PRx estimation from all hyperparameters using linear interpolation to match time points. The discrete-time empirical error was calculated as the difference between PRx from the hyperparameter and $\overline{PRx_{t_n}}$ defined previously. The standard deviation of the error over time was calculated as the standard deviation of the

discrete-time empirical error over all datasets, where $(d \in D)$ represents each dataset.

Standard Deviation of Empirical Error$_j$

$$= SD([\widehat{PRx_{t_n,j}} - \overline{PRx_{t_n}}]_{d \in D}) \qquad (5)$$

Statistical significance was calculated using a paired one-way ANOVA with multiple comparisons.

## III. RESULTS

### *PRx is Sensitive to Hyperparameters*

Using the 21 traumatic brain injury (TBI) patient datasets, we calculated PRx over a large range of hyperparameters. To validate our method, we plotted the PRx estimation present in the clinical dataset against our calculation with hyperparameters 10 seconds average and 30 samples of correlation (**PSupplemental Fig. 1**). 3 out of 21 datasets did not contain PRx estimation and were excluded from the validation step. The average lagged correlation for each dataset was 0.89, with a standard deviation of 0.05 and an average lag of -0.0160 seconds. We lagged the correlation because the PRx calculation is sensitive to the initial starting time, which is not recorded in the clinical dataset. The primary reason correlation was not equal to 1 was this time lag and differences in posterior quality control and artifact removal not available in the operational, clinical environment where clinical PRx was initially calculated. Given these differences, this correlation is strong enough to conclude that our PRx estimation is valid.

To assess whether empirical error in PRx was sensitive to hyperparameter choice, we first compared PRx estimation resulting from the five common hyperparameters given in **Table I**. The hyperparameter pair with ten-second averaging windows and 40 sample correlation had the lowest average empirical error and smallest uncertainty between the five common hyperparameters (**Fig. 3a**). Overall, shorter averaging windows (5-6 seconds) were positively biased (hyperparameter overestimates PRx compared to the mean), whereas longer averaging windows were negatively biased (hyperparameter underestimates PRx compared to the mean). These results indicate that across 21 datasets, PRx is sensitive to hyperparameter choices.

Because CPPopt is calculated by finding the CPP value for which PRx is minimized, we wanted to investigate whether the time and corresponding CPP for which PRx is minimized is also sensitive to hyperparameter choices, thereby directly impacting the CPPopt calculation used to guide clinical decision-making. **Figure 3b** shows the one-hour window around the time when PRx was minimized for three representative patient datasets (Roman numerals correspond to patient dataset numbers in **Fig. 3c**). For patient dataset **i** (**Fig. 3b**), PRx is minimized to a similar value at the same time for all hyperparameters. This represents the ideal situation. For patient dataset **iii** (Fig 3b), the value of PRx minimization ranges between very good CA (PRx = -0.6) for the three hyperparameters with long averaging windows (10-15 sec) and absent CA (PRx = 0.25) for the two hyperparameters with short averaging windows (5-6 sec), agreeing with our previous findings that different hyperparameters lead to varying interpretation of CA

function. In patient dataset **v** (**Fig 3b**), PRx is minimized at different times, ranging across 30 minutes. In this patient, we plotted the CPP (left y-axis in blue bars) at the times when PRx was minimized. Depending on the hyperparameter, optimal CPP ranged from 50 - 59 mmHg. These results indicate that the value of PRx, the time for which PRx reaches a minimum value, and the optimal CPP value are sensitive to hyperparameter choices.

### *Sensitivity to Hyperparameters is Patient Dependent*

While our results indicate that PRx is not robust to hyperparameter choices, if the behavior of the sensitivity is consistent across patients, one can quantify the error and control for it. Therefore, we chose to quantify the sensitivity for each patient. **Figure 3c** shows contour plots of the estimated median PRx over all hyperparameter combinations for five individual patients. The different colors on a single contour plot, corresponding to different PRx estimations, indicate that PRx is sensitive to hyperparameters, as shown previously. The different types of contours (e.g., horizontal (**ii.**) or diagonal and curved (**iv.** and **v.**)) indicate that the extent and behavior of PRx sensitivity are heterogeneous across patients. For example, in patient ii, using 18 correlation samples and 5, 6, or 7-second averaging windows results in median PRx values of 0.31, 0.28, and 0.17, respectively. This means that changing averaging window will change the PRx estimation by up to 82%.

To quantify sensitivity further, we defined the extent of PRx uncertainty as the range of PRx values for the five common methods. The difference in PRx estimation across the five common hyperparameters ranged was 0.054 for the least sensitive patient and 0.34 for the most sensitive patient (**Fig. 3c** right y-axis of scatter plot). Considering PRx can be between -1 and 1, this corresponds to an uncertainty in PRx between $2.5\% - 17\%$ of the possible PRx values when considering only the common hyperparameters. If we calculate the difference in PRx across all hyperparameters analyzed, PRx estimation had a minimum uncertainty of 0.32 and a maximum uncertainty of 1.57, corresponding to an uncertainty $16\% - 79\%$ across the possible PRx values (**Supp. Fig. 3**). We also quantify the global sensitivity at a granular level using the average percent change in PRx estimation given a small change in hyperparameter (1-second different averaging window, one sample different correlation window)(**Fig 3c** left y-axis of scatter plot). Results range from $1.6\% - 213\%$ depending on the patient, indicating that the influence of a small change of hyperparameters could make a large change in PRx estimation, and the amount of change in PRx is heterogeneous across patients.

The uncertainty of empirical error for each hyperparameter (**Fig. 3a**) also indicates that error is variable across patients. The hyperparameter pair with the lowest uncertainty was an averaging window of 10s and correlation window of 40 samples which had a range in empirical error of 0.28 across patients. Averaging window of 5 seconds and correlation window of 40 samples had the largest uncertainty with a range in empirical error of 0.49 across patients. Together, these results show that PRx is sensitive to hyperparameters, and the

Fig. 3. **PRx is Sensitive to Hyperparameters.** a) Empirical error of PRx estimation using the most common hyperparameters. Dots indicate single patient datasets. b) Time courses of PRx estimation using the most common hyperparameters for three representative patient datasets corresponding to those in c. Black circles indicate when PRx was minimized for each patient over four hours, highlighting that PRx minimization is sensitive to hyperparameter choices. In patient **v**, PRx is shown on the left y-axis and CPP for the time corresponding to PRx minimization is shown on the right axis. CPP bars are colored according to the corresponding hyperparameter where PRx was minimized. The dashed line indicates the range of CPP values where PRx was minimized. c) Quantified sensitivity to all hyperparameters analyzed. Contour plots show results from five representative patient datasets. The color indicates the PRx estimate. Differences in contour plot topography indicate that PRx sensitivity is patient-dependent. The scatter plot shows sensitivity and PRx range for all patient datasets, with black circles outlining five representative patient datasets whose contour plots are shown.

sensitivity of PRx is heterogenous across patients. *Therefore, a single hyperparameter choice can result in a different error for different patients, and a patient-specific adjustment to the PRx algorithm may be necessary for ensuring accuracy in PRx estimation for all patients.*

### PRx Error in Simulated Data is Dependent on CA Function

We then used the simulated data to evaluate the error of PRx estimation. To quantify hyperparameter-induced error compared to the true PRx value, we calculated PRx for all hyperparameter choices (as in patient data) for 600 datasets of simulated data. In general, all hyperparameters were least accurate for impaired CA and most accurate for functioning CA (**Supp. Fig. 2a**). In agreement with the patient data, larger averaging windows decreased uncertainty.

### Novel Heartrate Specific Methodology Reduces Error, Sensitivity to Hyperparameters, and Uncertainty in PRx Estimation

To test the hypothesis that personalizing the PRx algorithm will reduce error, patient sensitivity, and hyperparameter sensitivity, we first sought a source of patient-induced error that would be present in the time series currently used in the PRx algorithm. We first identified all heartbeats in the patient and simulated data (**Fig. 4a**). There was a clear nonlinear relationship between heart rate and error in the simulated dataset (**Fig. 4b**), with heart rate having the greatest effect in the impaired and absent CA cases and the least effect for intact CA. This relationship implies there may be a way to reduce patient-specific errors by reparameterizing PRx based on heartbeats.

To reparameterize the PRx algorithm using heartbeats while keeping alorithmic efficiency high, we chose to personalize the PRx algorithm by averaging over heartbeats rather than seconds. For example, if the hyperparameter pair was an

**Fig. 4.** **Heartbeat-Specific Averaging Improves PRx Estimation** a) Representative ABP signal from patient data with black lines indicating heartbeat start times (left). ABP (teal) and ICP (red) are averaged over a given number of these heartbeats (right). b) Dependence of median error in PRx calculation on heart rate for intact (blue), impaired (red), and absent (yellow) CA in simulated data. c) Error in PRx estimation using simulated data comparing heartbeat (blue) and seconds (standard, purple) averaging methods. d) Representative time series from patient data showing PRx estimation for the heartbeat method (blue) and seconds method (purple). e) Standard deviation of PRx over a four-hour window calculated by averaging over 10 seconds (purple) or heartbeats (blue) and correlating over 30 samples. Dots indicate each dataset. f) As in e but for range of PRx estimation amongst five common hyperparameters. g) As in e but for average value of empirical error. h) Empirical error comparing hearbeat method (blue) to seconds method (purple) for each patient dataset. i) Sorted median PRx in patient data for the heartbeat (blue) and seconds (purple) averaging methods. Arrows indicate that for patients with absent CA, the heartbeat method estimates a higher PRx than the seconds method, while the opposite is the case for functional CA. To test if heartbeat methodology improves PRx estimate, P-values in e,f, and g are one-tailed paired students' t-tests. Dots represent a single patient dataset

averaging window of ten seconds and correlation window of 30 samples, we instead averaged over ten heartbeats and correlated over 30 samples. This method will minimize the impact of intrapatient heart rate variability and interpatient average heartbeat differences. After identifying all heartbeats, we calculated PRx for all hyperparameters in both patient and simulated data using the new personalized heartbeat-based PRx algorithm.

In simulated data, the heartbeat method decreased the uncertainty of error in PRx and decreased average error (**Fig. 4c**, Table IV). As before, the uncertainty of error in PRx calculation is representative of how sensitive PRx accuracy is to different patients. Therefore, the heartbeat averaging method decreases both patient sensitivity and overall error in simulated data.

In patient data, the heartbeat method significantly decreased the noise in PRx, quantified by standard deviation over a patient's time series (**Fig. 4d,e**). The heartbeat method also significantly decreased the sensitivity to hyperparameters, quantified as the range of possible PRx values over all hyperparameters (Fig. 4f, Table IV) and the average percent change in PRx for a small change in hyperparameter (Table IV). This indicates that the heartbeat method is more robust to hyperparameters compared to the standard (seconds) method. The heartbeat method decreased the average empirical error (Fig. 4g,h, Table IV), indicating that the new method increases accuracy of PRx estimation. Further, the heartbeat method decreased standard deviation of the empirical error in patient data

*bold indicates better preformance

| | Standard Method | | Heartbeat Method | |
|---|---|---|---|---|
| Averaging (seconds or heartbeats) | 10 Sec | 10 Sec | 10 HB | 10 HB |
| Correlation (Samples) | 30 | 40 (optimal) | 30 | 40 |
| *Sensitivity of PRx Estimation to Hyperparameters* | | | | |
| Sensitivity: $\Delta PRx/\Delta window$ | 74.09% | | **55.21%**∗ | |
| Range of PRx Values | 0.20 | | **0.19\*** | |
| *Error in PRx estimation* | | | | |
| Maximum Absolute Value Empirical Error (patient) | -0.09 | -0.08 | **-0.05\*** | -0.06 |
| Standard Deviation of Empirical Error (patient) | 0.19 | 0.16 | 0.17 | **0.14\*** |
| Average Empirical Error (patient) | -0.02 | -0.03 | **-0.01\*** | -0.02 |
| Standard Deviation of Error (simulated) | 0.12 | 0.13 | **0.02\*** | **0.02\*** |
| Average Error (simulated) | -0.21 | -0.22 | **-0.18\*** | **-0.18\*** |

TABLE IV

**HEARTBEAT METHOD CONSISTENTLY DECREASES SENSITIVITY AND ERROR IN PRx ESTIMATION COMPARED TO STANDARD METHOD. BOLD VALUE\*** INDICATES A METHOD THAT HAS BETTER PERFORMANCE. COMPARISON BETWEEN HEARTBEAT METHOD AND STANDARD METHOD IN WAYS. **I. SENSITIVITY OF PRx ESTIMATION TO HYPERPARAMETERS.** SENSITIVITY IS CALCULATED ACROSS ALL HYPERPARAMETERS. SENSITIVITY: $\Delta PRx/\Delta WINDOW$ IS THE AVERAGE PERCENT CHANGE IN PRx FOR A SMALL CHANGE IN HYPERPARAMETER (FIG 3C). RANGE OF PRx VALUES SHOWS THE POSSIBLE RANGE OF PRx OVER THE FIVE COMMON HYPERPARAMETER CHOICES (FIG 3C). THE HEARTBEAT METHOD REDUCES SENSITIVITY ACCORDING TO BOTH METRICS. **II. ERROR IN PRx ESTIMATION.** MAXIMUM ERROR IS THE ERROR FOR THE PATIENT WITH THE LARGEST ERROR IN PRx ESTIMATION (FIG IV G, I.). STANDARD DEVIATION OF EMPIRICAL ERROR REPRESENTS HOW SENSITIVITE PRx IS TO PATIENT VARIABILITY ACROSS THE POPULATION. AVERAGE ERROR REPRESENTS THE MEAN ERROR FOR THE GIVEN METHOD AND HYPERPARAMETER SET. HEARTBEAT METHOD DECREASED MAXIMUM ERROR, AVERAGE ERROR, AND STANDARD DEVIATION OF ERROR IN PATIENT AND SIMULATED DATA.

(Fig. 4g,h, Table IV). Higher standard deviation of empirical error indicates PRx estimation is sensitive to patient variability across the population. Therefore, the heartbeat method reduces patient specific PRx error. The heartbeat averaging method did not notably impact PRx computation time. These results indicate that the heartbeat method reduces the uncertainty of error in PRx, decreases sensitivity to hyperparameters, and decreases patient sensitivity compared to the standard method in patient data.

Finally, we wanted to compare the difference in median PRx estimation from the heartbeat method vs the standard method. In the 21 patient datasets analyzed, median PRx estimation was not extremely different between the two averaging methodologies (Fig. 4i.), indicating that results from previous work with the standard PRx algorithm likely extend to the heartbeat method. However, for absent CA (PRx > 0.4), the heartbeat averaging methodology tended to estimate PRx to be larger than the estimate from the seconds averaging methodology. Our previous results in simulated data (Fig. 2a) indicate that the seconds averaging method underestimates PRx for patients with impaired and absent CA. Therefore, the heartbeat method may result in a more accurate PRx estimation.

## Optimal Hyperparameters in Standard Methodology Slightly Improves PRx Estimation

Despite the promise of this novel heartbeat-specific averaging, we also chose to investigate if there were optimal hyperparameters for the current non-personalized PRx algorithm. We identified the hyperparameter pairs that minimized the standard deviation (SD) of error (or empirical error) and average error for simulated and patient data, respectively (Fig 5a-d). The hyperparameters which minimized standard deviation and error in patient and simulated data were averaging windows between 9-10 seconds and correlation windows between 35-55 samples. The 10 second averaging 40 sample correlation hyperparameter pair was the only hyperparameter pair in Table I that fit within this range. Visually, the 10 seconds and 40 sample hyperparameter decreased uncertainty, or noise, over time (Fig 5e). This hyperparameter significantly decreased the standard deviation of empirical error over time compared to all other common hyperparameters (Fig 5f, table **??**).

## IV. DISCUSSION

Neurological and neurovascular injuries are a leading cause of death throughout the world. The pressure reactivity index (PRx) is a clinically important metric used to evaluate cerebral autoregulation (CA) function and guide clinical decision-making for patients with neurovascular and neurological injuries. PRx is calculated using two hyperparameters: the sizes of averaging and correlation windows. The objective of this study was to (i) quantify how sensitive PRx is to hyperparameters, (ii) investigate optimal hyperparameters for improving the robustness of PRx in the standard method, and (iii) develop a method to make PRx more robust to patient variability across the population.

## Recomendations Based on Findings

We conclude with two recommendations. In the current PRx algorithm, we recommend averaging windows between 9-10 seconds and correlation windows between 40-55 samples. Compared to other common hyperparameters, these hyperparameters significantly decrease uncertainty in PRx error in patient data (Fig. 5f). To further reduce uncertainty and remove patient specific error in PRx estimation, we have developed a new method that averages based on patient heart rate rather than seconds. *This patient-specific PRx algorithm decreases uncertainty, patient-specific sensitivity, and error in the PRx calculation, allowing for greater reliability of PRx and its use in clinical decision-making (Fig 4, Table IV).* The software for this new algorithm will be made publically available.

This new methodology is important because our data suggest that PRx sensitivity is patient-dependent (Fig. 3c.), indicating that personalizing the PRx algorithm to the patient's state may reduce error. The fact that PRx bias is associated with heart rate (Fig. 2) has important implications for healthcare equality. Heart rate variability and average resting heart rate are associated with age, ethnicity, and sex even after controlling for other health factors[42], [43]. Therefore, by personalizing the PRx estimation to heart rate, we remove algorithmic bias associated with age, ethnicity, and sex.

Fig. 5. Error in PRx estimation of all hyperparameters for simulated and patient data. a) Contour plots showing standard deviation (SD) of error in PRx for simulated data. Black hyperparameters indicate hyperparameters that minimized the SD of error for these data. b) Contour plots showing average error in simulated data. White indicates hyperparameters that minimized error. c) As in a but for patient data. d) As in c but for patient data. e) One hour time series of the standard deviation of empirical error for the five common hyperparameters. The optimal hyperparameter pair of averaging window of 10 seconds and correlation window of 40 samples lie within the optimal hyperparameter range and is bolded. f) Comparison between the standard deviation of empirical error for each time point. Averaging window of 10 seconds and correlation window of 40 samples had significantly smaller error ($p < 0.0001$) than other common hyperparameters. Analysis was paired one-way ANOVA with multiple comparisons.

PRx is valuable metric because it is fast to calculate and simple to interpret. By averaging over heartbeats, these benefits are maintained (as opposed to a more computationally expensive patient-specific method). Additionally, we were intentional in developing this new algorithm to only include data in the current PRx calculation. By doing so, we remove complications involved in updating current machinery to include new data, thereby increasing the likelihood and efficiency of adopting the new algorithm. However, more investigation should be conducted to determine if the use of additional information, such as electronic health records, can further reduce patient-specific errors.

While the heartbeat method outperformed the standard method, we also utilized our analysis to evaluate hyperparameters that minimized uncertainty in error for the standard method. We found the optimal averaging window to be between 9-10 seconds and optimal correlation window to be between 40-55 samples. From a data science perspective, it makes sense that the optimal averaging window in the current PRx algorithm is medium in length. Increasing the number of data points used for averaging will decrease bias. This is likely why larger averaging windows decreased bias and uncertainty in both synthetic and patient data. The same argument can explain why longer correlation windows decreased uncertainty. However, according to the sampling theorem, any frequency faster than half the width of the averaging window will be smoothed over and cannot be resolved[44]. Therefore, too long of an averaging window will not resolve essential frequencies

in CA and will not be able to distinguish between functional, impaired, and intact frequencies, which may be the case when using indices such as long-PRx [45].

The utility of our personalized heartbeat methodology and optimal hyperparameter recommendation was motivated by the results showing PRx is sensitive to hyperparameters, and this sensitivity is patient-dependent. As our sample size was relatively small, our results are likely a conservative estimate of the possible bias and sensitivity of PRx, because the prevalence of outliers generally increases as sample size increases.

We chose to analyze the sensitivity of PRx in a few different ways. If the error (Fig. 3a) for a given hyperparameter was relatively consistent across patients, one could consistently compare hyperparameters while considering this error. However, our data show that the error is patient and hyperparameter specific. Typically, PRx $> 0.25$ is interpreted as impaired CA and thought to predict a higher risk of mortality[28], [46], while PRx values $< 0$ are interpreted as intact CA. Therefore, the critical threshold between 'good' PRx and 'bad' is $\approx 0.25$. The range of possible PRx values allows us to quantify how sensitive PRx is to hyperparameters. In our cohort, the range of median PRx across the five common hyperparameters was between 0.054 and 0.34 (Fig 3c, scatter plot), with an average range is 0.20 (Table IV). This high level of hyperparameter influence (compared to the critical threshold of PRx) has important implications for clinical decision-making. The total range of empirical error was between 0.28 and 0.49 for the five different hyperparameters (Fig 3a), which is larger than

the critical threshold of PRx. This uncertainty indicates that PRx may have different interpretations across studies that use different hyperparameters and that raw PRx values may have different interpretations across individual patients.

We have analyzed how PRx estimation changes depending on hyperparameter choice, but it is not likely that a monitor would change hyperparameters throughout a patients stay. Therefore, one may argue that hyperparameter sensitivity would not influence PRx interpretation if only one hyperparameter pair was used. However, changes in hyperparameters can also be interpreted as missing data. Missing data or erroneous data is expected in ICU datasets. In a study of seven patients, there was an average of 166 segments of erroneous data per patient in a 24-hour period, and these segments had a large effect on PRx estimation**??**. Similarly, our findings show that missing data can greatly impact PRx estimation. For example, in figure 3c patient ii, missing one second of data per averaging window results in a change of median PRx estimation from 0.17 to 0.28, which crosses the critical threshold. Changes in correlation samples can be interpreted as missing a 5-30 second piece of data within a longer time. The average change in PRx given a change in hyperparameters was Therefore, because of the prevalence of missing data in clinical settings, the sensitivity of PRx to hyperparameters may be influential even when the algorithm is calculated using one hyperparameter pair.

Current clinical decision-making targets are not based on raw PRx values but rather on the CPP for which PRx is minimized (CPPopt). Decisions based on the wrong hyperparameter could guide decisions that cause over or underperfusion of the patient. Our results indicate that the time and CPP for which PRx is minimized may be hyperparameter dependent. However, the fact that CPPopt is calculated using a parabolic fit and averaging of PRx over the four-hour epoch[30] may help remove some of this uncertainty.

A central challenge in the study of PRx is that it cannot be directly validated in critically ill patients. Compared to other CA metrics, PRx is a more successful predictor of mortality[47], and in animals, PRx was shown to be a good predictor of the lower limit of autoregulation (AUC = 0.795 )[48], [49]. However, quantifying hyperparameter-dependent PRx error is not possible inpatient data. Therefore, we created simulated data using assumptions underlying PRx (see methods) and physiologically relevant frequencies. While the interpretation of simulated data is always limited, creating our simulated data based on assumptions made in the PRx allows us to probe these assumptions and quantify error.

## V. Conclusion

The pressure reactivity index (PRx) is an important proxy for cerebral autoregulatory function and shows great promise in aiding clinical decision-making for neurologically ill patients. In this manuscript, we show that PRx is sensitive to methodological hyperparameters and that this sensitivity is heterogenous across patients, partly due to differences in heart rate. Reducing this sensitivity is crucial for increasing the usefulness of PRx and CPPopt-guided clinical decision-making, particularly when PRx is applied to demographic groups with different average heart rates and heart rate variability. Therefore, we develop a novel methodology that personalizes the PRx algorithm to account for patient heart rate on a heartbeat resolution. *This new heartbeat methodology greatly reduces error, patient sensitivity, and hyperparameter sensitivity compared to the standard method.*

## References

[1] Centers for Disease Control and Prevention. National Center for Health Statistics, *Mortality Data on CDC WONDER*, Accessed April 2023, 2023. [Online]. Available: %7Bhttps://wonder.cdc.gov/mcd.html%7D.

[2] C. W. Tsao, A. W. Aday, Z. I. Almarzooq, *et al.*, "Heart disease and stroke statistics—2023 update: A report from the american heart association," *Circulation*, vol. 147, no. 8, e93–e621, 2023.

[3] N. Stocchetti and A. I. Maas, "Traumatic intracranial hypertension," *New England Journal of Medicine*, vol. 370, no. 22, pp. 2121–2130, 2014.

[4] N. A. Lassen, "Cerebral blood flow and oxygen consumption in man," *Physiological reviews*, vol. 39, no. 2, pp. 183–238, 1959.

[5] J. A. Claassen, D. H. Thijssen, R. B. Panerai, and F. M. Faraci, "Regulation of cerebral blood flow in humans: Physiology and clinical implications of autoregulation," *Physiological reviews*, vol. 101, no. 4, pp. 1487–1559, 2021.

[6] L. A. Steiner, M. Czosnyka, S. K. Piechnik, *et al.*, "Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury.," *Critical care medicine*, vol. 30, no. 4, pp. 733–738, 2002.

[7] J. Donnelly, M. Czosnyka, H. Adams, *et al.*, "Individualising thresholds of cerebral perfusion pressure using estimated limits of autoregulation," *Critical care medicine*, vol. 45, no. 9, p. 1464, 2017.

[8] A. I. Maas, D. K. Menon, P. D. Adelson, *et al.*, "Traumatic brain injury: Integrated approaches to improve prevention, clinical care, and research," *The Lancet Neurology*, vol. 16, no. 12, pp. 987–1048, 2017.

[9] N. Stocchetti, M. Carbonara, G. Citerio, *et al.*, "Severe traumatic brain injury: Targeted management in the intensive care unit," *The Lancet Neurology*, vol. 16, no. 6, pp. 452–464, 2017.

[10] M. Czosnyka, P. Smielewski, P. Kirkpatrick, R. J. Laing, D. Menon, and J. D. Pickard, "Continuous assessment of the cerebral vasomotor reactivity in head injury," *Neurosurgery*, vol. 41, no. 1, pp. 11–19, 1997, ISSN: 0148-396X.

[11] J. Tas, E. Beqiri, R. C. van Kaam, *et al.*, "Targeting autoregulation-guided cerebral perfusion pressure after traumatic brain injury (cogitate): A feasibility randomized controlled clinical trial," *Journal of Neurotrauma*, vol. 38, no. 20, pp. 2790–2800, 2021.

[12] E. Beqiri, P. Smielewski, C. Robba, *et al.*, "Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: The cogitate phase ii study protocol," *BMJ open*, vol. 9, no. 9, e030727, 2019.

[13] M. Czosnyka, P. Smielewski, P. Kirkpatrick, S. Piechnik, R. Laing, and J. Pickard, "Continuous monitoring of cerebrovascular pressure-reactivity in head injury," in *Intracranial Pressure and Neuromonitoring in Brain Injury*, Springer, 1998, pp. 74–77.

[14] G. Florence and J. Seylaz, "Rapid autoregulation of cerebral blood flow: A laser-doppler flowmetry study," *Journal of Cerebral Blood Flow & Metabolism*, vol. 12, no. 4, pp. 674–680, 1992.

[15] R. Aaslid, K.-F. Lindegaard, W. Sorteberg, and H. Nornes, "Cerebral autoregulation dynamics in humans.," *Stroke*, vol. 20, no. 1, pp. 45–52, 1989.

[16] F. A. Zeiler, A. Ercole, M. Czosnyka, *et al.*, "Continuous cerebrovascular reactivity monitoring in moderate/severe traumatic brain injury: A narrative review of advances in neurocritical care," *British journal of anaesthesia*, vol. 124, no. 4, pp. 440–453, 2020.

[17] M. P. Deisenroth, A. A. Faisal, and C. S. Ong, *Mathematics for machine learning*. Cambridge University Press, 2020, ch. 8.1.

[18] D. S. Wilks, *Statistical methods in the atmospheric sciences*. Academic press, 2011, vol. 100, ch. 6.

[19] A. Akhondi-Asl, F. W. Vonberg, C. C. Au, and R. C. Tasker, "Meaning of intracranial pressure-to-blood pressure fisher-transformed pearson correlation–derived optimal cerebral perfusion pressure: Testing empiric utility in a mechanistic model," *Critical care medicine*, vol. 46, no. 12, e1160, 2018.

[20] P. Smielewski, M. Czosnyka, L. Steiner, M. Belestri, S. Piechnik, and J. Pickard, "Icm+: Software for on-line analysis of bedside monitoring data after severe head trauma," in *Intracranial pressure and brain monitoring XII*, Springer, 2005, pp. 43–49.

[21] K. P. Budohoski, M. Czosnyka, N. de Riva, *et al.*, "The relationship between cerebral blood flow autoregulation and cerebrovascular pressure reactivity after traumatic brain injury," *Neurosurgery*, vol. 71, no. 3, pp. 652–661, 2012.

[22] K. M. Brady, J. K. Lee, K. K. Kibler, R. B. Easley, R. C. Koehler, and D. H. Shaffner, "Continuous measurement of autoregulation by spontaneous fluctuations in cerebral perfusion pressure: Comparison of 3 methods," *Stroke*, vol. 39, no. 9, pp. 2531–2537, 2008.

[23] P. Bijlenga, M. Czosnyka, K. P. Budohoski, *et al.*, ""optimal cerebral perfusion pressure" in poor grade patients after subarachnoid hemorrhage," *Neurocritical care*, vol. 13, no. 1, pp. 17–23, 2010.

[24] M. Czosnyka, Z. Czosnyka, and P. Smielewski, "Pressure reactivity index: Journey through the past 20 years," *Acta Neurochirurgica*, vol. 159, no. 11, pp. 2063–2065, 2017.

[25] C. Zweifel, G. Castellani, M. Czosnyka, *et al.*, "Non-invasive monitoring of cerebrovascular reactivity with near infrared spectroscopy in head-injured patients," *Journal of neurotrauma*, vol. 27, no. 11, pp. 1951–1958, 2010.

[26] T. Svedung Wettervik, T. Howells, P. Enblad, and A. Lewén, "Temporal neurophysiological dynamics in traumatic brain injury: Role of pressure reactivity and optimal cerebral perfusion pressure for predicting outcome," *Journal of neurotrauma*, vol. 36, no. 11, pp. 1818–1827, 2019.

[27] M. Rozanek, J. Skola, L. Horakova, and V. Trukhan, "Effect of artifacts upon the pressure reactivity index," *Scientific Reports*, vol. 12, no. 1, p. 15 131, 2022.

[28] C. Dias, M. J. Silva, E. Pereira, *et al.*, "Optimal cerebral perfusion pressure management at bedside: A single-center pilot study," *Neurocritical care*, vol. 23, no. 1, pp. 92–102, 2015.

[29] B. Depreitere, F. Güiza, G. Van den Berghe, *et al.*, "Pressure autoregulation monitoring and cerebral perfusion pressure target recommendation in patients with severe traumatic brain injury based on minute-by-minute monitoring data," *Journal of neurosurgery*, vol. 120, no. 6, pp. 1451–1457, 2014.

[30] M. J. Aries, M. Czosnyka, K. P. Budohoski, *et al.*, "Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury," *Critical care medicine*, vol. 40, no. 8, pp. 2456–2463, 2012.

[31] M. Jaeger, M. U. Schuhmann, M. Soehle, and J. Meixensberger, "Continuous assessment of cerebrovascular autoregulation after traumatic brain injury using brain tissue oxygen pressure reactivity," *Critical care medicine*, vol. 34, no. 6, pp. 1783–1788, 2006.

[32] T. Howells, U. Johnson, T. McKelvey, and P. Enblad, "An optimal frequency range for assessing the pressure reactivity index in patients with traumatic brain injury," *Journal of clinical monitoring and computing*, vol. 29, no. 1, pp. 97–105, 2015.

[33] M. Czosnyka, P. Hutchinson, M. Balestreri, M. Hiler, P. Smielewski, and J. Pickard, "Monitoring and interpretation of intracranial pressure after head injury," in *Brain Edema XIII*, Springer, 2006, pp. 114–118.

[34] D. K. Radolovich, M. Czosnyka, I. Timofeev, *et al.*, "Reactivity of brain tissue oxygen to change in cerebral perfusion pressure in head injured patients," *Neurocritical care*, vol. 10, no. 3, pp. 274–279, 2009.

[35] J. K. Yue, M. J. Vassar, H. F. Lingsma, *et al.*, "Transforming research and clinical knowledge in traumatic brain injury pilot: Multicenter implementation of the common data elements for traumatic brain injury," *Journal of neurotrauma*, vol. 30, no. 22, pp. 1831–1844, 2013.

[36] C. O. Tan, "Defining the characteristic relationship between arterial pressure and cerebral flow," *Journal of applied physiology*, vol. 113, no. 8, pp. 1194–1200, 2012.

[37] R. Zhang, J. H. Zuckerman, C. A. Giller, and B. D. Levine, "Transfer function analysis of dynamic cerebral autoregulation in humans," *American Journal of*

*Physiology-Heart and Circulatory Physiology*, vol. 274, no. 1, H233–H241, 1998.

[38] C. D. Fraser III, K. M. Brady, C. J. Rhee, *et al.*, "The frequency response of cerebral autoregulation," *Journal of Applied Physiology*, vol. 115, no. 1, pp. 52–56, 2013.

[39] T. Lescot, L. Naccache, M. Bonnet, L. Abdennour, P. Coriat, and L. Puybasset, "The relationship of intracranial pressure lundberg waves to electroencephalograph fluctuations in patients with severe head trauma," *Acta neurochirurgica*, vol. 147, no. 2, pp. 125–129, 2005.

[40] J. Hamner, M. A. Cohen, S. Mukai, L. A. Lipsitz, and J. A. Taylor, "Spectral indices of human cerebral blood flow control: Responses to augmented blood pressure oscillations," *The Journal of physiology*, vol. 559, no. 3, pp. 965–973, 2004.

[41] R. Steinmeier, C. Bauhuf, U. Hübner, *et al.*, "Slow rhythmic oscillations of blood pressure, intracranial pressure, microcirculation, and cerebral oxygenation: Dynamic interrelation and time course in humans," *Stroke*, vol. 27, no. 12, pp. 2236–2243, 1996.

[42] L. K. Hill, D. D. Hu, J. Koenig, *et al.*, "Ethnic differences in resting heart rate variability: A systematic review and meta-analysis," *Psychosomatic medicine*, vol. 77, no. 1, p. 16, 2015.

[43] Y. Ostchega, K. S. Porter, J. Hughes, C. F. Dillon, and T. Nwankwo, "Resting pulse rate reference data for children, adolescents, and adults; united states, 1999-2008," 2011.

[44] C. E. Shannon, "A mathematical theory of communication," *The Bell system technical journal*, vol. 27, no. 3, pp. 379–423, 1948.

[45] L. Riemann, E. Beqiri, P. Smielewski, *et al.*, "Low-resolution pressure reactivity index and its derived optimal cerebral perfusion pressure in adult traumatic brain injury: A center-tbi study," *Critical care*, vol. 24, no. 1, pp. 1–12, 2020.

[46] E. Sorrentino, J. Diedler, M. Kasprowicz, *et al.*, "Critical thresholds for cerebrovascular reactivity after traumatic brain injury," *Neurocritical care*, vol. 16, pp. 258–266, 2012.

[47] L. Rivera-Lara, A. Zorrilla-Vaca, R. Geocadin, *et al.*, "Predictors of outcome with cerebral autoregulation monitoring: A systematic review and meta-analysis," *Critical care medicine*, vol. 45, no. 4, pp. 695–704, 2017.

[48] F. A. Zeiler, J. Donnelly, L. Calviello, *et al.*, "Validation of pressure reactivity and pulse amplitude indices against the lower limit of autoregulation, part i: Experimental intracranial hypertension," *Journal of neurotrauma*, vol. 35, no. 23, pp. 2803–2811, 2018.

[49] F. A. Zeiler, J. K. Lee, P. Smielewski, M. Czosnyka, and K. Brady, "Validation of intracranial pressure-derived cerebrovascular reactivity indices against the lower limit of autoregulation, part ii: Experimental model of arterial hypotension," *Journal of neurotrauma*, vol. 35, no. 23, pp. 2812–2819, 2018.

Fig. 1. Validation of PRx against clinical PRx datasets. Blue indicated our lagged PRx estimate. Red represents PRx estimate output by clinical PRx datasets

Fig. 2. PRx error in simulated data. a) Error in PRx calculation for intact (left), impaired (middle), and absent (right) CA for five common hyperparameters.

## VI. Supplemental Figures

Fig. 3. Range of median PRx values over all hyperparameters analyzed